Literature DB >> 34107734

Activation of the Central Renin-Angiotensin System Causes Local Cerebrovascular Dysfunction.

T Michael De Silva1,2, Mary L Modrick1, Justin L Grobe3,4, Frank M Faraci1,3.   

Abstract

Background and Purpose: Hypertension is a leading risk factor for cerebrovascular disease and loss of brain health. While the brain renin-angiotensin system (RAS) contributes to hypertension, its potential impact on the local vasculature is unclear. We tested the hypothesis that activation of the brain RAS would alter the local vasculature using a modified deoxycorticosterone acetate (DOCA) model.
Methods: C57BL/6 mice treated with DOCA (50 mg SQ; or shams) were given tap H2O and H2O with 0.9% NaCl for 1 to 3 weeks.
Results: In isolated cerebral arteries and parenchymal arterioles from DOCA-treated male mice, endothelium- and nitric oxide-dependent dilation was progressively impaired, while mesenteric arteries were unaffected. In contrast, cerebral endothelial function was not significantly affected in female mice treated with DOCA. In males, mRNA expression of renal Ren1 was markedly reduced while RAS components (eg, Agt and Ace) were increased in both brain and cerebral arteries with central RAS activation. In NZ44 reporter mice expressing GFP (green fluorescent protein) driven by the angiotensin II type 1A receptor (Agtr1a) promoter, DOCA increased GFP expression ≈3-fold in cerebral arteries. Impaired endothelial responses were restored to normal by losartan, an AT1R (angiotensin II type 1 receptor) antagonist. Last, DOCA treatment produced inward remodeling of parenchymal arterioles. Conclusions: These findings suggest activation of the central and cerebrovascular RAS impairs endothelial (nitric oxide dependent) signaling in brain through expression and activation of AT1R and sex-dependent effects. The central RAS may be a key contributor to vascular dysfunction in brain in a preclinical (low renin) model of hypertension. Because the brain RAS is also activated during aging and other diseases, a common mechanism may promote loss of endothelial and brain health despite diverse cause.

Entities:  

Keywords:  cerebral arteries; disease; endothelium; hypertension; nitric oxide

Mesh:

Substances:

Year:  2021        PMID: 34107734      PMCID: PMC8262118          DOI: 10.1161/STROKEAHA.121.034984

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   10.170


  55 in total

Review 1.  Primary prevention of stroke: blood pressure, lipids, and heart failure.

Authors:  Matthias Endres; Peter U Heuschmann; Ulrich Laufs; Antoine M Hakim
Journal:  Eur Heart J       Date:  2011-02-01       Impact factor: 29.983

Review 2.  Regulation of the cerebral circulation: role of endothelium and potassium channels.

Authors:  F M Faraci; D D Heistad
Journal:  Physiol Rev       Date:  1998-01       Impact factor: 37.312

3.  Role of peroxisome proliferator-activated receptor-γ in vascular muscle in the cerebral circulation.

Authors:  T Michael De Silva; Mary L Modrick; Pimonrat Ketsawatsomkron; Cynthia Lynch; Yi Chu; Christopher J Pelham; Curt D Sigmund; Frank M Faraci
Journal:  Hypertension       Date:  2014-09-02       Impact factor: 10.190

4.  Changes in Cerebral Arteries and Parenchymal Arterioles With Aging: Role of Rho Kinase 2 and Impact of Genetic Background.

Authors:  T Michael De Silva; Mary L Modrick; Fabrice Dabertrand; Frank M Faraci
Journal:  Hypertension       Date:  2018-03-12       Impact factor: 10.190

Review 5.  Circulating biologic markers of endothelial dysfunction in cerebral small vessel disease: A review.

Authors:  Anna Poggesi; Marco Pasi; Francesca Pescini; Leonardo Pantoni; Domenico Inzitari
Journal:  J Cereb Blood Flow Metab       Date:  2016-01       Impact factor: 6.200

6.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

7.  Acetylcholine induces contraction in vergebral arteries from treated hypertensive patients.

Authors:  J R Charpie; K D Schreur; S M Papadopoulos; R C Webb
Journal:  Clin Exp Hypertens       Date:  1996-01       Impact factor: 1.749

8.  Endothelial Mineralocorticoid Receptor Mediates Parenchymal Arteriole and Posterior Cerebral Artery Remodeling During Angiotensin II-Induced Hypertension.

Authors:  Janice M Diaz-Otero; Courtney Fisher; Kelsey Downs; M Elizabeth Moss; Iris Z Jaffe; William F Jackson; Anne M Dorrance
Journal:  Hypertension       Date:  2017-10-03       Impact factor: 10.190

9.  Male-female differences in upregulation of vasoconstrictor responses in human cerebral arteries.

Authors:  Hilda Ahnstedt; Lei Cao; Diana N Krause; Karin Warfvinge; Hans Säveland; Ola G Nilsson; Lars Edvinsson
Journal:  PLoS One       Date:  2013-04-29       Impact factor: 3.240

10.  Nox2 contributes to age-related oxidative damage to neurons and the cerebral vasculature.

Authors:  Lampson M Fan; Li Geng; Sarah Cahill-Smith; Fangfei Liu; Gillian Douglas; Chris-Anne Mckenzie; Colin Smith; Gavin Brooks; Keith M Channon; Jian-Mei Li
Journal:  J Clin Invest       Date:  2019-07-22       Impact factor: 14.808

View more
  2 in total

1.  Plasma aldosterone concentration is associated with white matter lesions in patients with primary aldosteronism.

Authors:  Yujuan Yuan; Nanfang Li; Yan Liu; Menghui Wang; Mulalibieke Heizhati; Qing Zhu; Xiaoguang Yao; Qin Luo
Journal:  Endocrine       Date:  2021-11-15       Impact factor: 3.633

Review 2.  AT1 Receptors: Their Actions from Hypertension to Cognitive Impairment.

Authors:  Hanxue Wu; Qi Sun; Shenglan Yuan; Jiawei Wang; Fanni Li; Hongli Gao; Xingjuan Chen; Rui Yang; Jiaxi Xu
Journal:  Cardiovasc Toxicol       Date:  2022-02-24       Impact factor: 2.755

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.